Previous studies have demonstrated that EA might serve as a potential agent in the therapy of hepatic steatosis in patients with NAFLD by activation of AKT/mTORC1 signaling in the liver (Zhang et al., 2019). The gene discussed is AKT1; the disease is fatty liver disease.